GOSS Gossamer Bio (GOSS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001728117
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
91
13F, latest reported quarter
What the filings say about GOSS
Activist stakes (13D), 180 days
1 filing
Largest: 9.5% of the class
Gossamer Bio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Gossamer Bio, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 15, 2023.
- The trade is 44.9% of the 58,050 shares held after it.
- No other insider bought within 30 days.
- 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Milligan Sandra bought about $50.0K of GOSS on Aug 19, 2025, the largest insider purchase at the company since 2024; 91 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Mar 18, 2024.
- The trade is 1.0% of the 196,891 shares held after it.
- No other insider sold within 30 days.
- 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Aranda Richard sold about $1.3K of GOSS on Jun 24, 2024; 91 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (4 buys, 2 sales), the last on Mar 27, 2024.
- +10.2% median (+11.9% mean) 90-day return after 4 previous buys.
- The trade is 6.9% of the 5,408,073 shares held after it.
- 2 other insiders bought within 30 days.
- 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Hasnain Faheem bought about $249.2K of GOSS on Jun 21, 2024, the largest insider purchase at the company since 2023; 2 other insiders bought within 30 days and 91 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (4 buys, 2 sales), the last on Mar 27, 2024.
- +20.0% median (+22.1% mean) 90-day return after 4 previous buys.
- The trade is 20.8% of the 480,010 shares held after it.
- 2 other insiders bought within 30 days.
- 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO/CFO Giraudo Bryan bought about $59.0K of GOSS on Jun 18, 2024; 2 other insiders bought within 30 days and 91 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 25,000 shares held after it.
- 2 other insiders bought within 30 days.
- 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Smith Robert Paul JR bought about $15.0K of GOSS on Jun 17, 2024; 2 other insiders bought within 30 days and 91 funds added in the latest 13F quarter.41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
91 funds bought in last quarter
more than 65% of Pharma & Biotech
Revenue
-57.7% year over year
below 82% of Pharma & Biotech
Margin
-351.5% net margin
below 75% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
32.4% of the float short (float per yahoo 2026-10-26) · 3.5 days to cover · settled 2026-09-30
below 85% of Pharma & Biotech
The situation: each line is one rule over one dataset
D. E. Shaw Valence Portfolios, L.L.C. disclosed a 5%+ stake (9.0%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch GOSS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+337.8%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GOSS: institutional holders (13F)
13F holdings, latest reported quarter
40,959,285 sh
$6.7M
39,198,868 sh
$6.5M
37,665,073 sh
$6.0M
28,946,459 sh
$4.8M
25,017,881 sh
$4.1M
Congress trades in GOSS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
D. E. Shaw Valence Portfolios, L.L.C.
Activist 13D · 2026-06-11
9.0%
D. E. Shaw & Co., L.L.C.
Activist 13D · 2026-06-11
9.4%
D. E. Shaw & Co., L.P.
Activist 13D · 2026-06-11
9.5%
David E. Shaw
Activist 13D · 2026-06-11
9.5%
GOSS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
GOSS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Eventide Small Cap ETF
$34.7K position · as of 2026-07-31
0.1%
PACE Small/Medium Co Growth Equity Investments
$24.6K position · as of 2026-07-31
0.0%
SIIT SMALL CAP FUND
$10.9K position · as of 2026-05-31
0.0%
Invesco Russell 2000 Dynamic Multifactor ETF
$13.2K position · as of 2026-05-31
0.0%
Invesco Nasdaq Biotechnology ETF
$2.8K position · as of 2026-05-31
0.0%
Invesco RAFI US 1500 Small-Mid ETF
$94.3K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Faheem Hasnain
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.3M
$9.2M
$1.2M
+43%
n/a
2024
$2.0M
$1.9M
$1.1M
-58%
n/a
2023
$2.1M
$1.6M
$1.3M
-58%
n/a
2022
$7.3M
-$1.9M
$2.9M
-78%
n/a
2021
$4.8M
$6.3M
$2.2M
+17%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 91 funds added last quarter. Each figure is a federal filing, dated the day it went public.
GOSS financials
Revenue growth
-57.7%
XBRL, annual
Net margin
-351.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$53.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM GOSS
| FY Dec 2025 | $48.5M |
| FY Dec 2024 | $114.7M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $9.2M |
| Mar 2026 | $17.0M |
| Dec 2025 | $13.8M |
| Sep 2025 | $13.3M |
| Jun 2025 | $11.5M |
| Mar 2025 | $9.9M |
| Dec 2024 | $9.4M |
| Sep 2024 | $9.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-235.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM GOSS
| FY Dec 2025 | -351.5% |
| FY Dec 2024 | -49.3% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +182.9% |
| Mar 2026 | -275.2% |
| Dec 2025 | -342.3% |
| Sep 2025 | -362.7% |
| Jun 2025 | -333.1% |
| Mar 2025 | -370.5% |
| Dec 2024 | -352.2% |
| Sep 2024 | -324.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$162.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM GOSS
| FY Dec 2025 | -$171.3M |
| FY Dec 2024 | -$3.5M |
| FY Dec 2023 | -$159.2M |
| FY Dec 2022 | -$187.4M |
| FY Dec 2021 | -$190.4M |
| Jun 2026 | -$39.4M |
| Mar 2026 | -$38.7M |
| Dec 2025 | -$48.3M |
| Sep 2025 | -$36.2M |
| Jun 2025 | -$47.1M |
| Mar 2025 | -$39.8M |
| Dec 2024 | -$35.5M |
| Sep 2024 | -$32.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity GOSS
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.20x |
| FY Dec 2022 | 1.95x |
| FY Dec 2021 | 0.24x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt GOSS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -12.81x |
| FY Dec 2022 | -7.92x |
| FY Dec 2021 | -6.50x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity GOSS
| FY Dec 2025 | n/a |
| FY Dec 2024 | -122.5% |
| FY Dec 2023 | -480.5% |
| FY Dec 2022 | -343.5% |
| FY Dec 2021 | -105.8% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -783.4% |
| Mar 2025 | -500.6% |
| Dec 2024 | -122.5% |
| Sep 2024 | -90.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-78.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets GOSS
| FY Dec 2025 | -69.9% |
| FY Dec 2024 | -18.0% |
| FY Dec 2023 | -61.5% |
| FY Dec 2022 | -74.5% |
| FY Dec 2021 | -53.0% |
| Jun 2026 | -78.8% |
| Mar 2026 | -88.1% |
| Dec 2025 | -69.9% |
| Sep 2025 | -55.8% |
| Jun 2025 | -45.2% |
| Mar 2025 | -19.0% |
| Dec 2024 | -18.0% |
| Sep 2024 | -20.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital GOSS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-262.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed GOSS
| FY Dec 2025 | -90.1% |
| FY Dec 2024 | -22.6% |
| FY Dec 2023 | -76.0% |
| FY Dec 2022 | -83.0% |
| FY Dec 2021 | -53.7% |
| Jun 2026 | -262.8% |
| Mar 2026 | -117.3% |
| Dec 2025 | -90.1% |
| Sep 2025 | -72.0% |
| Jun 2025 | -56.5% |
| Mar 2025 | -24.0% |
| Dec 2024 | -22.6% |
| Sep 2024 | -24.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing GOSS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.4B
market value at close 2026-10-26 on 2026-08-08 shares, plus long-term 2024-12-31 (18 months older than the period end) plus current 2024-12-31 (18 months older than the period end), minus cash 2026-06-30
Enterprise value GOSS
| FY Dec 2025 | $679.8M |
| FY Dec 2024 | $159.0M |
| FY Dec 2023 | $186.1M |
| FY Dec 2022 | $116.6M |
| FY Dec 2021 | $710.5M |
| Jun 2026 | -$2.4M |
| Mar 2026 | $36.2M |
| Dec 2025 | $679.8M |
| Sep 2025 | $589.1M |
| Jun 2025 | $253.3M |
| Mar 2025 | $220.9M |
| Dec 2024 | $159.0M |
| Sep 2024 | $194.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield GOSS
| FY Dec 2025 | -23.9% |
| FY Dec 2024 | -1.7% |
| FY Dec 2023 | -77.3% |
| FY Dec 2022 | -91.4% |
| FY Dec 2021 | -22.0% |
| Jun 2026 | -420.0% |
| Mar 2026 | -220.6% |
| Dec 2025 | -23.9% |
| Sep 2025 | -26.5% |
| Jun 2025 | -55.2% |
| Mar 2025 | +3.6% |
| Dec 2024 | -1.7% |
| Sep 2024 | -0.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing GOSS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | $0 | $0 |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M |
| Net income | -$170.4M | -$56.5M | -$179.8M | -$229.4M |
| EPS (diluted) | -0.75 | -0.25 | -1.18 | -2.71 |
| Operating cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.0M |
| Cash | $37.7M | $46.1M | $32.1M | $112.0M |
| Long-term debt | n/a | $0 | $814.0K | $12.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
GOSS Stock Sonar score 4/7 axes
Find similar shapesCompareGOSS ranks highest on institutional and government (65th percentile) and risk and compliance (23rd), and lowest on growth (18th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
GOSS filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 9.5% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
